tradingkey.logo
搜索

Veracyte Inc

VCYT
添加自选
57.080USD
-2.770-4.63%
收盘 07/02, 13:00美东报价延迟15分钟
4.53B总市值
51.19市盈率 TTM

Veracyte Inc

57.080
-2.770-4.63%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-4.63%

5天

-5.64%

1月

+17.23%

6月

+34.65%

今年开始到现在

+35.58%

1年

+107.49%

关键数据
59.920今开
60.584最高
1.15M成交量
51.19市盈率 TTM
47.03市盈率动
--股息TTM
1.45%换手率
59.850昨收
56.500最低
52.06M成交额
187.66市盈率静
3.46市净率
0.00%股息率 TTM
6.40%ROA
50.71052周最高
1.14量比
24.14M净利润
79.36M总股本
1.1150每股收益TTM
1.98Beta
6.93%ROE
22.61052周最低
6.82%振幅
72.32%毛利率
4.53B总市值
7.21回报/风险
2.75%风险率

TradingKey Veracyte Inc股票评分

单位: USD 更新时间: 2026-07-02

操作建议

Veracyte Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名14/387位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价51.18。中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Veracyte Inc评分

相关信息

行业排名
14 / 387
全市场排名
63 / 4565
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
极度看好

Veracyte Inc亮点

亮点风险
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
业绩高增长
公司营业收入稳步增长,连续3年增长43.23%
估值合理
公司最新PE估值51.19,处于3年历史合理位
机构减仓
最新机构持股96.10M股,环比减少1.93%
凯茜·伍德(木头姐)持仓
明星投资者凯茜·伍德(木头姐)持仓,最新持仓市值2.21M
活跃度增加
近期活跃度增加,过去20天平均换手率0.50

分析师目标

根据 12 位分析师
买入
评级
52.545
目标均价
-12.20%
涨幅空间

Veracyte Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Veracyte Inc简介

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
公司代码VCYT
公司Veracyte Inc
CEOStapley (Marc A)
网址https://www.veracyte.com/

常见问题

Veracyte Inc(VCYT)的当前股价是多少?

Veracyte Inc(VCYT)的当前股价是 57.08。

Veracyte Inc的股票代码是什么?

Veracyte Inc的股票代码是VCYT。

Veracyte Inc股票的52周最高点是多少?

Veracyte Inc股票的52周最高点是50.71。

Veracyte Inc股票的52周最低点是多少?

Veracyte Inc股票的52周最低点是22.61。

Veracyte Inc的市值是多少?

Veracyte Inc的市值是4.53B。

现在Veracyte Inc(VCYT)的股票是买入、持有还是卖出?

根据分析师评级,Veracyte Inc(VCYT)的总体评级为买入,目标价格为52.55。

Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是多少

Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是0.84。